EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA
Recommended Citation
Hanft S, Elder B, Giglio P, Wu SH, Farrell C, Alnahhas I, Lee IY, Walbert T, Boockvar J, Vojnic M, Zacharia B, Aregawi D, Kim L, Schulder M, Ghatan S, Singer S, Silva Correia CE, Ramakrishna R, Wu J, Jeyapalan S, Magge R, Patel N, Agarwal V, Bhatia A, Brennan C, Evans L, Gill B, Sengupta S, Wong ET. EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro Oncol 2024; 26(Suppl 5):V67-V68.
Document Type
Conference Proceeding
Publication Date
10-17-2024
Publication Title
Neuro Oncol
Volume
26
Issue
Suppl 5
First Page
V67
Last Page
V68
